Innate Pharma S.A. ( (IPHYF) ) has released its Q4 earnings. Here is a breakdown of the information Innate Pharma S.A. presented to its investors.
Innate Pharma S.A. is a clinical-stage biotechnology company focused on developing immunotherapies for cancer, utilizing its proprietary ANKET® platform, Antibody Drug Conjugates, and monoclonal antibodies. The company is headquartered in Marseille, France, and is listed on Euronext Paris and Nasdaq in the US.
In its 2024 financial results, Innate Pharma highlighted several key developments, including the FDA granting Breakthrough Therapy Designation for lacutamab in Sézary syndrome, and the initiation of a Phase 1 study for IPH4502 in solid tumors. The company also reported a cash position of €91.1 million, extending its cash runway to mid-2026.
Financially, Innate Pharma faced a challenging year with a significant decrease in revenue from collaboration and licensing agreements, amounting to €20.1 million, down from €61.6 million in 2023. Operating expenses saw a slight decrease to €71.7 million, while the net loss widened to €49.5 million from €7.6 million the previous year. The company continues to focus on its strategic partnerships with Sanofi and AstraZeneca to drive innovation and development.
Looking ahead, Innate Pharma remains committed to advancing its clinical programs and leveraging its strong partnerships to deliver innovative therapies. The management is optimistic about its strategic direction and financial management, which supports its goal of bringing new treatments to patients.